TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TNGX

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/08	06:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/06/08	06:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/06/08	06:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/06/07	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/06/05	20:00	Business Wire	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/23	22:18	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/23	20:18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/23	20:00	Business Wire	Tango Therapeutics Announces Discontinuation of TNG348 Program	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20:00	Business Wire	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2024/04/02	05:48	Business Wire	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/18	20:00	Business Wire	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/06	21:00	Business Wire	Tango Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/06	06:47	GlobeNewswire Inc.	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/09	11:09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/09	11:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/07	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/06	06:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/06	06:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/31	21:00	GlobeNewswire Inc.	Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/06	06:05	GlobeNewswire Inc.	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/04	16:47	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/03	21:00	GlobeNewswire Inc.	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/13	21:00	GlobeNewswire Inc.	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21:29	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21:00	GlobeNewswire Inc.	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/07	21:00	GlobeNewswire Inc.	Tango Therapeutics to Present at the Jefferies London Healthcare Conference	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/03	05:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc